Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,802 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07090759RecruitingPhase 3
Test of new drug for hepatitis B not fully controlled by current treatment
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hangzhou, ZhejiangAges 18–70 - NCT07091357RecruitingPhase 2
Study of SHR-1819 for seasonal allergies
This trial tests an injection called SHR-1819 for people with seasonal allergic rhinitis (hay fever) that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it helps reduce allergy symptoms during pollen season.
Beijing, Beijing MunicipalityAges 18–75 - NCT07118241RecruitingPhase 2
Testing a new eye drop for Sjögren's dry eye
This trial tests a new eye drop made from a natural protein (rhPRG4) to see if it safely and effectively relieves dry eye symptoms in people with Sjögren's syndrome. You'll be randomly assigned to receive the study drop or a placebo (inactive) drop for several weeks.
Sydney, New South WalesAges 18–80 - NCT07118254RecruitingPhase 2
Eye drops for dry eye from graft-versus-host disease
This study tests whether a new eye drop (rhPRG4) can safely reduce dry eye symptoms caused by graft-versus-host disease (GVHD). It compares the active drops to an inactive placebo to see if they provide better relief.
Sydney, New South WalesAges 18–75 - NCT07132515RecruitingPhase 4
Blood thinners for cirrhosis with portal vein clot
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
Al Mansurah, Dakahlia GovernorateAges 18–70 - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07136181RecruitingPhase 1/Phase 2
Study of NBM-BMX for advanced uveal melanoma that has spread
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Scottsdale, ArizonaAges 18 years+ - NCT07138144RecruitingPhase 4
Switching to a two-drug HIV pill vs. staying on three drugs
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Mexico City, Mexico CityAges 18–70 - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Glendale, CaliforniaAges 18–85 - NCT07169214RecruitingPhase 1
Study of BT-114143 injection for heavy menstrual bleeding
This trial tests an investigational medication called BT-114143 for people with heavy menstrual bleeding (abnormal uterine bleeding). The goal is to see if it is safe and effective in reducing blood loss during periods.
Beijing, Beijing MunicipalityAges 18–50 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07186413RecruitingPhase 3
Comparing trifarotene cream vs placebo for moderate acne
This study tests a cream to treat moderate acne on the face and possibly upper body. It is for Chinese participants aged 9 and older.
Shanghai, Jing'an DistrictAges 9 years+ - NCT07190209RecruitingPhase 3
Testing lunsekimig for COPD with frequent flare-ups
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
Chandler, ArizonaAges 40–80 - NCT07190222RecruitingPhase 3
New medicine for COPD with frequent flare-ups
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Birmingham, AlabamaAges 40–80 - NCT07193901RecruitingPhase 2
Nasal spray for depression with suicidal thoughts
This trial tests an experimental nasal spray for people with major depression who are currently having suicidal thoughts. It aims to see if the spray can quickly reduce depression and suicidal feelings.
BeijingAges 18–64 - NCT07203001RecruitingPhase 2
MAS825 for Still's disease in children and adults
This trial tests a new drug called MAS825 for people with Still's disease that is still active despite other treatments. It aims to see if the drug can reduce symptoms like fever, rash, joint pain, or a serious complication called macrophage activation syndrome.
Cincinnati, OhioAges 1–100 - NCT07215702RecruitingPhase 2
Testing a drug for kidney injury from sepsis in the ICU
This trial tests if a new drug, AZD4144, can help people with sepsis-related acute kidney injury in the ICU. It aims to see if the drug can improve kidney recovery and reduce complications.
Tucson, ArizonaAges 18–80 - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT07304089RecruitingPhase 2
Study of VIM0423 for people with dystonia
This trial tests an experimental drug called VIM0423 for people with isolated dystonia (a condition causing muscle spasms in multiple body parts). It aims to see if the drug can improve symptoms safely.
Birmingham, AlabamaAges 18–65 - NCT07308548RecruitingPhase 2
Testing HP515 for fatty liver disease (NASH/MASH)
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07365462RecruitingPhase 2
Study of NBI-1065890 for tardive dyskinesia in adults
This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.
Bryant, ArkansasAges 18–75 - NCT07371338RecruitingPhase 1
Testing a new drug for advanced Parkinson's
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
SeoulAges 50–80
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,802 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.